Conference Coverage

Small Study: Reduced Anti-TNF Dose Still Effective

Publish date: June 25, 2012

 

AT THE ANNUAL MEETING OF THE EUROPEAN CONGRESS OF RHEUMATOLOGY

Dr. Gibson said that she had no disclosures.

Pages

Recommended Reading

Certolizumab Eased Skin and Joint Symptoms in PsA
MDedge Rheumatology
Rheumatoid Arthritis Etiology Includes Occupational Exposures
MDedge Rheumatology
Three Erosive Joints Made New RA Definition
MDedge Rheumatology
Hydroxychloroquine Cuts Diabetes Risk in Rheumatoid Arthritis
MDedge Rheumatology
Spondyloarthropathy Common a Decade After IBD Diagnosis
MDedge Rheumatology
Tofacitinib to Jockey With Anti-TNFs for RA Role
MDedge Rheumatology
Watch for Renal Comorbidities in Ankylosing Spondylitis
MDedge Rheumatology
Switching TNF Inhibitors Pays in Ankylosing Spondylitis
MDedge Rheumatology
Interleukin-17 Inhibitor Scores in Rheumatoid Arthritis Trial
MDedge Rheumatology
Is Tocilizumab Monotherapy for RA Losing Luster?
MDedge Rheumatology